Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5997994 | 0.90 | ATM (0.52) | MAPTALDH1A1ATMTDP1LMNA | |
| SCHEMBL5998418 | 0.85 | ALDH1A1 (0.46) | MAPTALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL5998122 | 0.82 | ANPEP (0.44) | MAPTALDH1A1CA1CA2CA9 | |
| SCHEMBL5998754 | 0.82 | MAPT (0.46) | MAPTALDH1A1ATMTDP1LMNA | |
| SCHEMBL5997974 | 0.81 | ALDH1A1 (0.41) | MAPTALDH1A1ATMMEN1KMT2A | |
| SCHEMBL5998719 | 0.81 | ALDH1A1 (0.44) | MAPTALDH1A1TDP1CA1CA2 | |
| SCHEMBL5998387 | 0.80 | ALDH1A1 (0.49) | MAPTALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL5998072 | 0.80 | TTR (0.40) | MAPTALDH1A1TDP1LMNAMEN1 | |
| SCHEMBL29217854 | 0.78 | CA1 (0.55) | MAPTALDH1A1ATMTDP1LMNA | |
| SCHEMBL2283350 | 0.77 | LMNA (0.51) | MAPTALDH1A1ATMTDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7094908-B2 | Reduction of carbonyl compounds using the carbonyl reductase of Kluyveromyces marxianus | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2006-08-22 | — | — | US | disclosed |
| US-20030139464-A1 | Reduction of carbonyl compounds using the carbonyl reductase of kluyveromyces marxianus | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139464-A1 | Reduction of carbonyl compounds using the carbonyl reductase of kluyveromyces marxianus | CBR1, CBR3, DCXR | MAPT 3262/4885ALDH1A1 216/4885ATM 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.